| Debra K Pendleton, LPN | |
|
131 Wagon Trl, Bowling Green, KY 42103-9030 | |
| (270) 792-1803 | |
| Not Available |
| Full Name | Debra K Pendleton |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 131 Wagon Trl, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275208258 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 2035466 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Debra K Pendleton, LPN 131 Wagon Trl, Bowling Green, KY 42103-9030 Ph: (270) 792-1803 | Debra K Pendleton, LPN 131 Wagon Trl, Bowling Green, KY 42103-9030 Ph: (270) 792-1803 |
News Archive
Agilex Technologies, Inc., a leading provider of mission and technology solutions to the national security, healthcare and public sectors, announced today it was named the region's fastest growing company by the Washington Business Journal. In the company's first year of eligibility, Agilex debuted at the top of the list with reported three year growth of 372.32% and total revenue of $38M (FY2009). This annual ranking covers the entire Washington, DC metro area.
The Elizabeth Glaser Pediatric AIDS Foundation today announced that it will join the Population Council and a prestigious consortium of leading HIV research organizations as part of a five-year project funded by the U.S. Agency for International Development. The Supporting Operational AIDS Research project aims to conduct operational HIV and AIDS research, promote utilization and dissemination of data, and build the capacity of local organizations to conduct operational research.
According to the latest research obese women are more impulsive than other females but this does not apply to obese men.
Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.
Research has documented that black Americans are systematically undertreated for pain relative to white Americans, likely due to both the over-prescription and over-use of pain medications among white patients and the under-prescription of pain medications for black patients.
› Verified 2 days ago
Thelma Stearman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 628 Crossings Ct, Bowling Green, KY 42104 Phone: 270-779-5204 |